Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mochida Pharmaceutical Co Ltd Obtains Manufacturing and Marketing Permission


Friday, 28 Dec 2012 01:00am EST 

Mochida Pharmaceutical Co Ltd announced that it has obtained the manufacturing and marketing permission for its treatment aiming hyperlipidemia and arteriosclerosis obliterans, as switch Over The Counter (OTC) drug, on December 28, 2012. 

Company Quote

6330.0
-30.0 -0.47%
24 Oct 2014